AhmadGhorabMD, MS, MPH

PubMed

• 1 citations
  Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs.
  Ahmad Ghorab, Aref Al-Kali, Michelle Elliot, Naseema Gangat, Hasan Alkhateeb, Mithun Shah, Yuanhang Liu, Cecilia Arana Yi, Hemant Murthy, Mohamed Kharfan-Dabaja, Ayale...> ;Blood Cancer Journal. 2022 Jun 24
• 19 citations
  Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant ...
  Iman Abou Dalle, Ahmad Ghorab, Keyur P. Patel, Xuemei Wang, Hyunsoo Hwang, Jorge E. Cortes, Ghayas C. Issa, Fevzi Firat Yalniz, Koji Sasaki, Dai Chihara, Allyson Price...> ;Blood Cancer Journal. 2020 May 4
• 76 citations
  Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
  Preetesh Jain, Rashmi Kanagal-Shamanna, Shaojun Zhang, Makhdum Ahmed, Ahmad Ghorab, Liang Zhang, Chi Young Ok, Shaoying Li, Frederick B. Hagemeister, Dongfeng Zeng, Ti...> ;British Journal of Haematology. 2018 Nov 1
• 93 citations
  Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
  Preetesh Jain, Hagop M. Kantarjian, Ahmad Ghorab, Koji Sasaki, Elias J. Jabbour, Graciela M. Nogueras González, Rashmi Kanagal-Shamanna, Ghayas C. Issa, Guillermo Garc...> ;Cancer. 2017 Nov 15
• Join now to see all

Lectures

• Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib E... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Impact of numerical variation, allele burden and mutation length on outcomes in acute myeloid leukemia with fms-like tyrosine kinase receptor-3 internal tandem duplica... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018